Patents by Inventor Judy Caron

Judy Caron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ADMINISTERING TOLPERISONE
    Publication number: 20200390754
    Abstract: The present disclosure provides methods of treating a subject with a daily regimen of tolperisone effective against muscle spasm or spastic syndrome. The regimen is effective without impairing cognitive function, and may improve cognitive function, as measured by various cognitive and alertness tests.
    Type: Application
    Filed: November 19, 2018
    Publication date: December 17, 2020
    Inventors: Judy Caron, Jeff Raser
  • MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME
    Publication number: 20180000792
    Abstract: Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided.
    Type: Application
    Filed: February 13, 2017
    Publication date: January 4, 2018
    Applicant: BIONEVIA PHARMACEUTICALS INC.
    Inventors: Isabel KALOFONOS, Judy CARON, William MARTIN-DOYLE
  • Modified release compositions of epalrestat or a derivative thereof and methods for using the same
    Patent number: 9566269
    Abstract: Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: February 14, 2017
    Assignee: Bionevia Pharmaceuticals Inc.
    Inventors: Isabel Kalofonos, Judy Caron, William Martin-Doyle
  • COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION
    Publication number: 20140343069
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Applicant: Sunovion Inc.
    Inventors: Karim LALJI, Timothy BARBERICH, Judy CARON, Thomas WESSEL
  • Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20140315910
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 23, 2014
    Inventors: Judy Caron, Thomas Wessel, Karim LALJI, Mark Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Han, Stefan G. Koenig
  • MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME
    Publication number: 20140296309
    Abstract: Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided.
    Type: Application
    Filed: January 20, 2012
    Publication date: October 2, 2014
    Applicant: BIONEVIA PHARMACEUTICALS INC.
    Inventors: Isabel Kalofonos, Judy Caron, William Martin-Doyle
  • Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine
    Patent number: 8329950
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: December 11, 2012
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Han, Stefan G. Koenig
  • Methods of treatment of chronic pain using eszopiclone
    Patent number: 8247417
    Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: August 21, 2012
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas Wessel, Judy Caron
  • Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20120123164
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 17, 2012
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Judy CARON, Thomas Wessel, Karim Lalji, Mark A. Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Steve Han, Stefan G. Koenig
  • COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION
    Publication number: 20120122874
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 17, 2012
    Applicant: Sunovion Inc.
    Inventors: Karim LALJI, Timothy J. BARBERICH, Judy CARON, Thomas WESSEL
  • METHODS OF TREATMENT OF CHRONIC PAIN USING ESZOPICLONE
    Publication number: 20120035182
    Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
    Type: Application
    Filed: October 12, 2011
    Publication date: February 9, 2012
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Thomas Wessel, Judy Caron
  • Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
    Patent number: 8097625
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: January 17, 2012
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Karim Lalji, Timothy J. Barberich, Judy Caron, Thomas Wessel
  • Methods of treatment of chronic pain using eszopiclone
    Patent number: 8071599
    Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: December 6, 2011
    Assignee: Sunovion Pharmaceuticals, Inc.
    Inventors: Thomas Wessel, Judy Caron
  • METHODS OF TREATMENT OF CHRONIC PAIN USING ESZOPICLONE
    Publication number: 20100280038
    Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
    Type: Application
    Filed: July 19, 2010
    Publication date: November 4, 2010
    Applicant: SEPRACOR INC.
    Inventors: Thomas Wessel, Judy Caron
  • Methods of treatment of chronic pain using eszopiclone
    Patent number: 7776858
    Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: August 17, 2010
    Assignee: Sepracor Inc.
    Inventors: Thomas Wessel, Judy Caron
  • Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20090111818
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: July 5, 2006
    Publication date: April 30, 2009
    Applicant: SEPRACOR INC.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney
  • Combinations of Eszopiclone and an Antidepressant
    Publication number: 20090111817
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: July 5, 2006
    Publication date: April 30, 2009
    Applicant: SEPRACOR INC.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney
  • Methods of treatment of menopause and perimenopause using eszopiclone
    Patent number: 7465729
    Abstract: The invention relates to the use of eszopiclone for the treatment of symptoms accompanying perimenopause or menopause.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: December 16, 2008
    Assignee: Sepracor Inc.
    Inventors: Thomas Wessel, Judy Caron
  • Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20080293726
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: July 6, 2006
    Publication date: November 27, 2008
    Applicant: SEPRACOR INC.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Steve Han, Stefan G. Koenig
  • Treatment of anxiety with eszopiclone
    Publication number: 20080175903
    Abstract: The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.
    Type: Application
    Filed: December 1, 2007
    Publication date: July 24, 2008
    Applicant: Sepracor Inc.
    Inventors: Seth C. Hopkins, Mark A. Varney, Tushar Misra, Gary Maier, Judy Caron, Randall S. Wagner